EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Host Cell Protein Clinical Safety Risk Assessment—An Updated Industry Review

Lisette Coye, Marisa A Jones, Georgeen Gaza-Bulseco, Carmelata Chitikila, Severine Clavier iD, Delphine Fougeron, Christine Grimaldi iD, Karen Hurkmans, Richard Hutchinson iD, Brenda Kellogg, Xinrong Liu, Nisha Palackal iD und 8 weitere

Biotechnology and Bioengineering · 2025-11 · 122 (11) · 3229-3248

DOI: 10.1002/bit.70029 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biotechnology and Bioengineering, online erschienen am 04.08.2025. Verfasst von Lisette Coye und 19 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc., Pharmaceutical Sciences, Bothell, Washington, USA. Hauptthemen laut MEDLINE: Biological Products, Drug Industry, Patient Safety, Drug Contamination. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Financial support for this manuscript was provided by BioPhorum Operations Group..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Host cell proteins (HCP) are process‐related impurities that can co‐purify with therapeutic proteins. Some HCP impurities potentially can have an impact on patient safety (immunogenicity or toxicity), efficacy, and/or product quality. It is important to reduce the levels of HCP impurities with a well‐controlled manufacturing process and to monitor levels with a suitable analytical assay. Biopharmaceutical companies are now routinely using mass spectrometry to identify HCPs which are present in process intermediates and potentially in bulk drug substances and using the data to make decisions to continuously improve their processes and mitigate the potential risk to patients. Some companies perform identification of HCPs starting from the nonclinical stage of development, while others perform HCP identification at later stages or as a part of root cause analysis for identified HCP ELISA‐related issues, process, and product quality or safety concerns. No matter the approach, a comprehensive risk assessment framework for identified HCPs is needed to support decision‐making during development and is expected by regulators to ensure a safe and efficacious drug product. In this paper the BioPhorum Development Group HCP Workstream has brought together a team of industry experts to build upon existing risk assessment frameworks (e.g., de Zafra et al., 2015) and developed recommendations for assessment of clinical safety risks upon identification of individual HCPs, incorporating regulatory considerations and industry experience and using a real‐world case study to illustrate the use of the updated frameworks. Key recommendations include conducting clinical risk assessment alongside product quality risk assessment following individual HCP identification and quantitation; focusing on biological activity and immunogenicity for any HCPs of concern; and communicating and collaborating effectively across functions to enable a comprehensive risk assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsDrug IndustryPatient SafetyDrug ContaminationRisk AssessmentHumans

Stichwörter der Autor:innen

MS/HCP‐MSPLBL2clinical safety riskhigh‐risk HCPshost cell proteinsimmunogenicityrisk assessment

Substanzen

Biological Products

Autor:innen und Institutionen

  • Pfizer Inc., Pharmaceutical Sciences, Bothell, Washington, USA.
  • GSK, Collegeville, Pennsylvania, USA.
  • AbbVie Bioresearch Center, Analytical Development, Worcester, Massachusetts, USA.
  • Johnson & Johnson, Therapeutics Development and Supply, Analytical Development, Malvern, Pennsylvania, USA.
  • Sanofi R&D, BioAnalytics, Global CMC Development, Vitry-sur-seine, France.
  • Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.

ORCID-Profile: Severine Clavier, Christine Grimaldi, Richard Hutchinson, Nisha Palackal, Thomas Waerner, Fengqiang Wang, Sapphire Sloan, Christina Zuch de Zafra

Förderung

  • Financial support for this manuscript was provided by BioPhorum Operations Group.

Zitieren

APA

Coye, L., Jones, M. A., Gaza-Bulseco, G., Chitikila, C., Clavier, S., Fougeron, D., Grimaldi, C., Hurkmans, K., Hutchinson, R., Kellogg, B., Liu, X., Palackal, N., Tank, M., Valax, P., Waerner, T., Wang, F., Zhang, Y., Zhao, Y., Sloan, S., & de Zafra, C. Z. (2025). Host Cell Protein Clinical Safety Risk Assessment—An Updated Industry Review. Biotechnology and Bioengineering, 122(11), 3229-3248. https://doi.org/10.1002/bit.70029

Vancouver

Coye L, Jones MA, Gaza-Bulseco G, Chitikila C, Clavier S, Fougeron D, et al. Host Cell Protein Clinical Safety Risk Assessment—An Updated Industry Review. Biotechnology and Bioengineering. 2025;122(11):3229-3248. doi:10.1002/bit.70029

BibTeX
@article{Coye2025,
  author = {Coye, Lisette and Jones, Marisa A and Gaza-Bulseco, Georgeen and Chitikila, Carmelata and Clavier, Severine and Fougeron, Delphine and Grimaldi, Christine and Hurkmans, Karen and Hutchinson, Richard and Kellogg, Brenda and Liu, Xinrong and Palackal, Nisha and Tank, Mahima and Valax, Pascal and Waerner, Thomas and Wang, Fengqiang and Zhang, Ying and Zhao, Yiwei and Sloan, Sapphire and de Zafra, Christina Zuch},
  title = {Host Cell Protein Clinical Safety Risk Assessment—An Updated Industry Review},
  journal = {Biotechnology and Bioengineering},
  year = {2025},
  volume = {122},
  number = {11},
  pages = {3229--3248},
  doi = {10.1002/bit.70029}
}
Kostenlos starten →